Placebo Inhalation Powder NDPI

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

AsthmaPulmonary Disease, Chronic Obstructive

Phase 3

Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

CompletedNCT01181895

GlaxoSmithKlineAsthma

Start: 2010-09-01End: 2011-08-26Updated: 2017-11-08

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01706328

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2012-10-15End: 2013-06-17Updated: 2018-05-02

Related Papers

Genetic effects on efficacy to fluticasone propionate/salmeterol treatment in COPD.

2019-06-291 citations

Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients

Respiratory Medicine2014-06-1829 citations

Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids.

2014-06-1315 citations